Statistics from Altmetric.com
Licensed medicines for paediatric patients
In the last two decades, international legislation has been introduced to try to ensure that medicines for use in children are of high quality, ethically researched and authorised appropriately.1 2 This is stimulating improvements in the research and development of suitable paediatric medicines by increasing the number of licensed products (see box 1) with reliable evidence-based dosing and safety profiles.
No suitable licensed product available, what’s next?
Although these improvements in legislation have encouraged and promoted the licensing of paediatric medicines, there are still many patients receiving unlicensed medicines due to a lack of available suitable licensed products.
Studies across Europe have shown that at least one-third of children in hospital and up to 90% of neonates in neonatal intensive care receive unlicensed medicines (see boxes 2 and 3).4 Similarly, previous UK studies of paediatric populations within primary care show that unlicensed and/or off-label medicines are used around 11% of the time.5
A medicinal product that does not have a marketing authorisation. The medicine has not been assessed for efficacy, safety and quality to the same standards as a licensed product.
Types of unlicensed medicines15
‘Off-Label’: use of a medicine outside the terms of its licence, for example, licensed for intravenous administration but administered orally.
‘Extemporaneous (magistral)’: preparation through manipulation of a medicine into a powder or a suspension for an individual patient by a pharmacist.
‘Special’: medicines made by a pharmaceutical manufacturer under a Manufacturing Specials licence (UK specific).
‘Imported’: medicines with a licence from another country …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.